 Aptevo Therapeutics Inc. APVO, a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has completed dosing in a single ascending dose SAD Phase 1 study of APVO210, a novel investigational bispecific antibody candidate being developed for the treatment of autoimmune diseases. Preliminary data from the SAD study show that single ascending doses of APVO210 did not cause any adverse events of concern or dose-limiting toxicities, nor were any anti-drug antibodies observed in the study based on patient samples obtained to date. As a result, Aptevo has received approval to begin the next phase of the study, evaluating multiple ascending doses of APVO210 in healthy volunteers. 